A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.

被引：0
|
作者：
Li, Huiping
Zhang, Jiayang
Yin, Rutie
Song, Nan
Zhang, Youzhong
Zhang, Yu
Zhang, Keqiang
Pan, Hongming
Wang, Ke
Lou, Ge
Li Guiling
Zhang, Ben
Wang, Quanren
Gao, Yunong
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Breast Oncol, Minist Educ Beijing, Beijing, Peoples R China
[2] Sichuan Univ, Dept Gynecol & Obstet, West China Univ Hosp 2, Chengdu, Peoples R China
[3] Sichuan Univ, West China Univ Hosp 2, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Minist Educ, Chengdu, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Dept Gynecol Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
[5] Shangdong Univ, Dept Obstet & Gynecol, Qilu Hosp, Shandong, Peoples R China
[6] Cent South Univ, Xiangya Hosp, Med Eth Comm, Changsha, Peoples R China
[7] Hunan Canc Hosp, Gynecol Oncol Ward 5, Changsha, Peoples R China
[8] Zhejiang Univ, Dept Med Oncol, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China
[9] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[10] Harbin Med Univ, Gynecol Ward 1, Canc Hosp, Harbin, Peoples R China
[11] Huazhong Univ Sci & Technol, Union Hosp, Dept Gynecol Oncol, Tongji Med Coll, Wuhan, Peoples R China
[12] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
[13] Beijing Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5539
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Qingyuan Zhang
    Bin Shao
    Zhongsheng Tong
    Quchang Ouyang
    Yuting Wang
    Guoying Xu
    Shaorong Li
    Huiping Li
    BMC Medicine, 20
  • [2] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Zhang, Qingyuan
    Shao, Bin
    Tong, Zhongsheng
    Ouyang, Quchang
    Wang, Yuting
    Xu, Guoying
    Li, Shaorong
    Li, Huiping
    BMC MEDICINE, 2022, 20 (01)
  • [3] A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
    Yaxin Liu
    Wei Wang
    Rutie Yin
    Youzhong Zhang
    Yu Zhang
    Keqiang Zhang
    Hongming Pan
    Ke Wang
    Ge Lou
    Guiling Li
    Ruyan Zhang
    Kun Li
    Jing Rao
    Ben Zhang
    Yuting Wang
    Quanren Wang
    Yunong Gao
    Huiping Li
    BMC Medicine, 21
  • [4] A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
    Liu, Yaxin
    Wang, Wei
    Yin, Rutie
    Zhang, Youzhong
    Zhang, Yu
    Zhang, Keqiang
    Pan, Hongming
    Wang, Ke
    Lou, Ge
    Li, Guiling
    Zhang, Ruyan
    Li, Kun
    Rao, Jing
    Zhang, Ben
    Wang, Yuting
    Wang, Quanren
    Gao, Yunong
    Li, Huiping
    BMC MEDICINE, 2023, 21 (01)
  • [5] Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.
    Westin, Shannon Neville
    Litton, Jennifer Keating
    Williams, Rochelle A.
    Shepherd, Christopher J.
    Brugger, Wolfram
    Pease, Elizabeth J.
    Soliman, Pamela T.
    Frumovitz, Michael M.
    Levenback, Charles F.
    Sood, Anil
    Meyer, Larissa
    Moulder, Stacy L.
    Valero, Vicente
    Saleem, Sadia
    Rodriguez, Anna Marie
    Cyriac, Annies
    Engerman, Laverne
    Samuel, Christine
    Mills, Gordon B.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
    Liu, Joyce F.
    Tolaney, Sara M.
    Birrer, Michael
    Fleming, Gini F.
    Buss, Mary K.
    Dahlberg, Suzanne E.
    Lee, Hang
    Whalen, Christin
    Tyburski, Karin
    Winer, Eric
    Ivy, Percy
    Matulonis, Ursula A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (14) : 2972 - 2978
  • [7] Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.
    Cotte, Alexia
    Beniey, Michele
    Haque, Takrima
    Bechir, Nelly
    Hubert, Audrey
    Diallo, Korotoum W.
    Tran-Thanh, Danh
    Hassan, Saima N.
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Characterization of PARP inhibitor combination therapies in triple-negative breast cancer
    Fyle, Elicia
    Abdesselam, Djihane
    Frederick, Mallory
    Hassan, Saima N.
    CANCER RESEARCH, 2023, 84 (06)
  • [9] A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer
    Liu, J.
    Fleming, G. F.
    Tolaney, S. M.
    Birrer, M. J.
    Penson, R. T.
    Berlin, S. T.
    Whalen, C.
    Tyburski, K.
    Matijevich, K.
    Kasparian, E.
    Roche, M.
    Lee, H.
    Winer, E. P.
    Ivy, S. P.
    Matulonis, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Phase 3 Trial with PARP1 Inhibitor, BSI-201, Launched for the treatment of metastatic Triple-negative breast cancer.
    不详
    ONKOLOGIE, 2010, 33 (04):
12345